Home › Funds › ANTIPODES PARTNERS Ltd › JNJ

ANTIPODES PARTNERS Ltd position in JNJ

JOHNSON & JOHNSON · Health Care

ANTIPODES PARTNERS Ltd reported holding 91,816 shares of JNJ (JOHNSON & JOHNSON) in its Q2 2026 13F filing — a position valued at US$23.3M, representing 0.43% of its reported portfolio and ranking #50 among its reported holdings. ANTIPODES PARTNERS Ltd has disclosed JNJ holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

Latest position (Q2 2026)91.82K sh
Reported value held$23.32M
Portfolio Weight0.43%
First reportedQ2 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ANTIPODES PARTNERS Ltd's JNJ position evolved

ANTIPODES PARTNERS Ltd first disclosed a stake in JNJ in Q2 2025 at 152,032 shares (US$23.2M). The position peaked in Q3 2025 at 155,963 shares, worth US$28.9M. Across 5 filings, ANTIPODES PARTNERS Ltd increased the stake 1 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 91,816 shares valued at US$23.3M — a reduction of -9,207 shares quarter over quarter.. Notable position changes include a 25% trim in Q4 2025 (shares rose 18% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 152.03K $23.22M New
Q3 2025 155.96K $28.92M Add
Q4 2025 116.81K $24.17M Reduce
Q1 2026 101.02K $24.69M Reduce
Q2 2026 91.82K $23.32M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About JNJ and 13F data

JNJ (JOHNSON & JOHNSON) is a Health Care company. 33 other funds we track also report a position in JNJ — the largest reported positions include BlackRock Inc (US$53.87B), Vanguard Group (US$49.74B), VANGUARD CAPITAL MANAGEMENT LLC (US$39.93B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding JNJ

All JNJ fund holders →

FAQ

How long has ANTIPODES PARTNERS Ltd held JNJ?

ANTIPODES PARTNERS Ltd has disclosed JNJ holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

What is ANTIPODES PARTNERS Ltd's current position in JNJ?

As of Q2 2026, ANTIPODES PARTNERS Ltd holds 91.82K shares of JNJ (JOHNSON & JOHNSON), valued at $23.32M, representing 0.43% of its reported portfolio and ranking #50.

Has ANTIPODES PARTNERS Ltd been buying or selling JNJ?

In the latest 13F filing (Q2 2026), ANTIPODES PARTNERS Ltd reduced its position in JNJ. The position peaked in Q3 2025 at 155.96K shares.

Which other funds hold JNJ?

Other major institutional holders of JNJ include BlackRock Inc, Vanguard Group, VANGUARD CAPITAL MANAGEMENT LLC, among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.